Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Alexander I. Spira(Virginia Cancer Specialists), David Raben(University of Colorado Denver), David Planchard(Institut Gustave Roussy), Byoung Chul Cho(Yonsei University), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Davey B. Daniel(Sarah Cannon), Augusto Villegas(Florida Cancer Specialists & Research Institute), David Vicente(Hospital Universitario Virgen Macarena), Rina Hui(The University of Sydney), S. Murakami(Kanagawa Prefectural Hospital Organization), David R. Spigel(Sarah Cannon), Suresh Senan(Amsterdam University Medical Centers), Corey J. Langer(University of Pennsylvania), Bradford A. Perez(Moffitt Cancer Center), A-M. Boothman(AstraZeneca (United Kingdom)), Helen Broadhurst, Catherine Wadsworth(AstraZeneca (United Kingdom)), P. Dennis(AstraZeneca (United States)), Scott Antonia(Moffitt Cancer Center), Corinne Faivre‐Finn(University of Manchester)
Cited by 222Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis